RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery

PHASE2TerminatedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Heart Valve DiseaseCoronary Artery Disease
Interventions
DRUG

Human fibrinogen concentrate

4 g IV once, within 30 minutes of ACT \< 155 seconds, post CPB, with evidence of significant microvascular bleeding

OTHER

apheresis platelets

A single apheresis platelet unit will be administered as an initial therapy within 30 minutes of ACT \<155 seconds post CPB with evidence of significant microvascular bleeding.

Trial Locations (1)

30322

Emory University Hospital, Atlanta

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

CSL Behring

INDUSTRY

lead

Emory University

OTHER